References
- Camps P, El Achab R, Morral J, et al. New tacrine-huperzine A hybrids (huprines): highly potent tight-binding acetylcholinesterase inhibitors of interest for the treatment of Alzheimer’s disease. J Med Chem 2000; 43: 4657–4666.
- Wang ZF, Tang LL, Yan H, et al. Effects of huperzine A on memory deficits and neurotrophic factors production after transient cerebral ischemia and reperfusion in mice. Pharmacol Biochem Behav 2006; 83: 603–611.
- Darrouzain F, Dallet P, Dubost JP, et al. Molecular lipophilicity determination of a huperzine series by HPLC: comparison of C18 and IAM stationary phases. J Pharm Biomed 2006; 41: 228–232.
- Liu WH, Song JL, Liu K, et al. Preparation and in vitro and in vivo release studies of huperzine A loaded microspheres for the treatment of Alzheimer’s disease. J Control Release 2005; 107: 417–427.
- Tang LL, Wang R, Tang XC. Huperzine A protects SHSY5Y neuroblastoma cells against oxidative stress damage via nerve growth factor production. Eur J Pharmacol 2005; 519: 9–15.
- Wang R, Yan H, Tang XC. Progress in studies of huperzine A, a natural cholinesterase inhibitor from Chinese herbal medicine. Acta Pharmacol Sin 2006; 27: 1–26.
- Yu H, Li WM, Kan KKW, et al. The physicochemical properties and the in vivo AChE inhibition of two potential anti-Alzheimer agents, bis(12)-hupyridone and bis(7)-tacrine. J Pharm Biomed 2008; 46: 75–81.
- Sun QQ, Xu SS, Pan JL. Huperzine-A capsules enhance memory and learning performance in 34pairs of matched adolescent students. Acta Pharmacol Sin 1999; 20: 601–603.
- Xu SS, Guo ZX, Wang Z. Efficacy of tablet huperzine A on memory, cognition, and behavior in Alzheimer’s disease. Acta Pharmacol Sin 1995; 16: 391–395.
- Lin LC, Wang MN, Tseng TY, et al. Pharmacokinetics of (−)- epigallocatechin-3-gallate in conscious and freely moving rats and its brain regional distribution. J Agric Food Chem 2007; 55: 1517–1524.
- Pazos M, Andersen ML, Medina I, et al. Efficiency of natural phenolic compounds regenerating ß-tocopherol from β-tocopheroxyl radical. J Agric Food Chem 2007; 55: 3661–3666.
- Bose M, Hao X, Ju J, et al. Inhibition of tumorigenesis in ApcMin/+mice by a combination of (−)-epigallocatechin-3-gallate and fish oil. J Agric Food Chem 2007; 55: 7695–7700.
- Yano S, Fujimura Y, Umeda D, et al. Relationship between the biological activities of methylated derivatives of (−)-epi- gallocatechin-3-O-gallate (EGCG) and their cell surface binding activities. J Agric Food Chem 2007; 55: 7144–7148.
- Uekusa Y, Kamihira M, Nakayama T. Dynamic behavior of tea catechins interacting with lipid membranes as determined by NMR spectroscopy. J Agric Food Chem 2007; 55: 9986–9992.
- Ellmann GL, Courtney KD, Andres V, et al. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol 1961; 7: 88–95.
- Xiao J, Chen X, Zhang L, et al. Investigation on the mechanism of enhanced effect of EGCG on huperzine A inhibiting acetylcholinesterase activity in rats by multi-spectroscopic method. J Agric Food Chem 2008; 56: 910–915.
- Zeng F, Jiang H, Zhai Y, et al. Synthesis and acetylcholinesterase inhibitory activity of huperzine-E2020 combined compound. Bioorg Med Chem Lett 1999; 9: 3279–3284.
- Shen SR, Yu HN, Jin CE. Isolation and purification of huperzine A. J Zhejiang Univ A 2002; 25: 591–594.
- Ma X, Tan C, Zhu D, et al. A survey of potential huperzine A natural resources in China: the Huperziaceae. J Ethnopharmacol 2006; 104: 54–67.
- Yamada F, Kozikowski AP, Reddy ER, et al. A route to optically pure (−)-huperzine A; molecular modeling and in vitro pharmacology. J Am Chem Soc 1991; 113: 4695–4696.
- Zhang B, Osborne NN. Oxidative-induced retinal degeneration is attenuated by EGCG. Brain Res 2006; 1124: 176–187.
- Huen MS, Hui KM, Leung JW, et al. Naturally occurring 2′- hydroxyl-substituted flavonoids as high affinity benzodiazepine site ligands. Biochem Pharmacol 2003; 66: 2397–2407.